Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country
Main Article Content
Keywords
Bronchiolitis, Hospitalization costs, Length of stay, Respiratory syncytial virus
Abstract
Introduction and objectives: With the objective of making informed decisions on resource allocation, there is a critical need for studies that provide accurate information on hospital costs for treating respiratory syncytial virus (RSV)-related bronchiolitis, mainly in middle-income countries (MICs). The aim of the present study was to evaluate the direct medical costs associated with bronchiolitis hospitalizations caused by infection with RSV in Bogota, Colombia.
Material and methods: We reviewed the available electronic medical records (EMRs) for all infants younger than two years of age who were admitted to the Fundacion Hospital de La Misericordia with a discharge principal diagnosis of RSV-related bronchiolitis over a 24-month period from January 2016 to December 2017. Direct medical costs of RSV-related bronchiolitis were retrospectively collected by dividing the infants into three groups: those requiring admission to the pediatric ward (PW) only, those requiring admission to the pediatric intermediate care unit (PIMC), and those requiring to the pediatric intensive care unit (PICU).
Results: A total of 89 patients with a median (IQR) age of 7.1 (3.1-12.2) months were analyzed of whom 20 (56.2%) were males. Overall, the median (IQR) cost of infants treated in the PW, in the PIMC, and in the PICU was US$518.0 (217.0-768.9) vs. 1305.2 (1051.4-1492.2) vs. 2749.7 (1372.7-4159.9), respectively, with this difference being statistically significant (p < 0.001).
Conclusions: The present study helps to further our understanding of the economic burden of RSV-related bronchiolitis hospitalizations among infants of under two years of age in a middle-income tropical country.
References
2. Calvo C, Pozo F, Garcia-Garcia ML, et al. Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatrica (Oslo, Norway: 1992). 2010;99:883-7.
3. Miller EK, Gebretsadik T, Carroll KN. Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatric Infect Dis J. 2013;32:950-5.
4. Skjerven HO, Megremis S, Papadopoulos NG, Mowinckel P, Carlsen KH, Lodrup Carlsen KC. Virus type and genomic load in acute bronchiolitis: severity and treatment response with inhaled adrenaline. J Infect Dis. 2016;213:915-21.
5. Scheltema NM, Gentile A, Lucion F. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Global Health. 2017;5:e984-91.
6. Hall CB, Weinberg GA, Blumkin AK. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132:e341-8.
7. Berman S. Epidemiology of acute respiratory infections in children of developing countries. Rev Infect Dis. 1991;13 Suppl. 6:S454-62.
8. Hall CB, Weinberg GA, Iwane MK. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588-98.
9. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003;88:1065-9.
10. Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ. 2012;15:987-96.
11. Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Cost effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ. 2012;15:997-1018.
12. Novavax. Corporate update. http://novavax.com/presentation.show [accessed 11.07.18].
13. Gamba-Sanchez N, Rodriguez-Martinez CE, Sossa-Briceno MP. Epidemic activity of respiratory syncytial virus is related to temperature and rainfall in equatorial tropical countries. Epidemiol Infect. 2016;144:2057-63.
14. Banco de la República, Colombia. Series estadísticas. Tasas de cambio. Santa Fe de Bogotá: Banco de la República; 2011. Available from: http://www.banrep.gov.co/series-estadisticas/see ts cam.htm [accessed 11.07.18].
15. Heikkila P, Forma L, Korppi M. Hospitalisation costs for infant bronchiolitis are up to 20 times higher if intensive care is needed. Acta Paediatrica (Oslo, Norway: 1992). 2015;104:269-73.
16. Buendia JA, Sinisterra D. Cost illness of RSV infection in Colombia. Am J Respir Crit Care Med. 2018;197:A3686.
17. Lara-Oliveros CA, De Graeve D, Franco F, Daza SP. Disease burden and medical cost-analysis of Acute Respiratory Infections in a low-income district of Bogota. Revista de Salud Publica (Bogota Colombia). 2016;18:568-80.
18. McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. J Perinatol. 2016;36:990-6.
19. Katz BZ, Lo J, Sorrentino M. Costs of respiratory syncytial virus infection at a tertiary-care children’s hospital. P and T. 2003;28:343-5.
20. Creery D, Lyer P, Samson L, Coyle D, Osborne G, MacDonald A. Costs associated with infant bronchiolitis in the Baffin region of Nunavut. Int J Circumpolar Health. 2005;64:38-45.
21. Pelletier AJ, Mansbach JM, Camargo CA Jr. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics. 2006;118:2418-23.
22. Stang P, Brandenburg N, Carter B. The economic burden of respiratory syncytial virus-associated bronchiolitis hospitalizations. Arch Pediatrics Adolesc Med. 2001;155:95-6.
23. Himmelstein DU, Jun M, Busse R. A comparison of hospital administrative costs in eight nations: US costs exceed all others by far. Health Affairs (Project Hope). 2014;33:1586-94.
24. Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA. 2018;319:1024-39.
25. Dieleman JL, Squires E, Bui AL. Factors associated with increases in US health care spending, 1996-2013. JAMA. 2017;318:1668-78.
26. Bont L, Aalderen WM, Kimpen JL. Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatr Respir Rev. 2000;1:221-7.
27. Amand C, Tong S, Kieffer A, Kyaw MH. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis. BMC Health Serv Res. 2018;18:294.
28. Palmer L, Hall CB, Katkin JP. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants. Pediatr Pulmonol. 2010;45:772-81.
29. Igde M, Kabasakal H, Ozturk O, Karatekin G, Aygun C. Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma. Minerva Pediatr. 2018;70:252-9.
30. Kovesi T. Palivizumab prophylaxis and recurrent wheezing. Am J Respir Crit Care Med. 2018;197:679-80.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.